Europe

English

Respiratory conditions have a significant societal and economic cost, with the burden negatively affecting healthcare systems, impacting the lives of patients and their families, lowering productivity and widening the gap in life expectancy between the poorest and wealthiest.

There is a gap in policy commitment, especially around prevention and diagnosis, for the most frequently diagnosed respiratory conditions, despite a continued rise in incidence and mortality rates across Europe.

  1. Global Burden of Disease, “Global Burden of Disease”, 2019, https://vizhub.healthdata.org/gbd-results/
  2. Global Burden of Disease, “Global Burden of Disease”, 2019, https://vizhub.healthdata.org/gbd-results/
  3. Global Burden of Disease, “Global Burden of Disease”, 2019, https://vizhub.healthdata.org/gbd-results/
  4. This figure provides a benchmark societal value for the economic burden of respiratory diseases to inform investment strategies. Calculated in terms of monetised loss of disability-adjusted life years (DALYs), the benchmark societal cost for the most significant respiratory conditions across the WHO European region. Download the data used to calculate the DALY societal rate
  5. This figure provides a benchmark societal value for the economic burden of respiratory diseases to inform investment strategies. Calculated in terms of monetised loss of disability-adjusted life years (DALYs), the benchmark societal cost for the most significant respiratory conditions across the European Union. Download the data used to calculate the DALY societal rate
  • Disability-adjusted life years (DALYs) rate
  • Disability-adjusted life years (DALYs) numbers
  • Monetised DALYS – societal costs by disease